Prospective Grant of Exclusive License: Devices for Countercurrent Chromatography, 57595-57596 [E7-19941]
Download as PDF
Federal Register / Vol. 72, No. 195 / Wednesday, October 10, 2007 / Notices
Date: October 29–30, 2007.
Time: 8 a.m. to 9 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Virtual Meeting).
Contact Person: Malgorzata Klosek, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4188,
MSC 7849, Bethesda, MD 20892, 301–435–
2211, Klosekm@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: October 2, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–4991 Filed 10–9–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice Meeting
Notice is hereby given of a change in
the meeting of the Pathobiology of
Kidney Disease Study Section, October
11, 2007, 8 a.m. to October 12, 2007, 5
p.m., Hotel Rouge, 1315 16th Street,
NW., Washington, DC 20036 which was
published in the Federal Register on
September 21, 2007, 72 FR 54051–
54054.
The meeting will be held one day
only—October 11, 2007, 8 a.m. to 6 p.m.
The meeting location remains the same.
The meeting is closed to the public.
Dated: October 2, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–4993 Filed 10–9–07; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
rwilkins on PROD1PC63 with NOTICES
National Institute of Allergy and
Infectious Diseases, Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
17:08 Oct 09, 2007
Jkt 214001
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel.
Date: November 6, 2007.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge 6700, 6700B Rockledge Drive,
Bethesda, MD 20817. (Telephone Conference
Call).
Contact Person: Paul A. Amstad, Ph.D.,
Scientific Review Administrator, Scientific
Review Program, Division of Extramural
Activities, DHHS/National Institutes of
Health/NIAID, 6700B Rockledge Drive, MSC
7616, Bethesda, MD 20892–7616, 301–402–
7098, pamstad@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS).
Dated: October 3, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–4990 Filed 10–9–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Statement of Organization, Functions,
and Delegations of Authority
BILLING CODE 4140–01–M
VerDate Aug<31>2005
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Part N, National Institutes of Health
(NIH), of the Statement of Organization,
Functions, and Delegations of Authority
for the Department of Health and
Human Services (DHHS) (40 FR 22859,
May 27, 1975, as amended most recently
at 71 FR 1446, January 9, 2006, and
redesignated from Part HN as Part N at
60 FR 56605, November 9, 1995), is
amended as set forth below to reflect the
transfer of the bioengineering and
physical science functions from the
Office of the Director, Office of
Management, Office of Research
Services (NAM5, formerly HNAM5), to
the National Institute of Biomedical
Imaging and Bioengineering (N8,
formerly HN8).
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
57595
Section N–B, Organization and
Functions, is amended by replacing the
current section N86 (formerly HN86)
with the following:
Intramural Research Programs (N86,
formerly HN86). Responsible for all
aspects of NIBIB intramural research,
including staffing, facilities, and
research programs. Also includes the
Laboratory of Bioengineering and
Physical Science, which contributes to
the advancement of NIH research by the
application of engineering,
mathematics, and the physical sciences
to the solution of problems in biology
and medicine through (1) consultations
and collaborative research with NIH
intramural scientists in the areas of
measurement, imaging, mathematical
analysis, and modeling and the design
of specialized research protocols and
equipment; (2) proposing and
developing theoretical and experimental
methods, including novel
instrumentation, to meet long-term
needs of the NIH Intramural Research
Program; and (3) serving as a liaison to
other NIH and non–NIH organizations
with bioengineering and physical
science expertise to obtain and
disseminate information on
technological resources and
development applicable to NIH
intramural research problems.
Section N–B, Organization and
Functions, under the heading ‘‘Office of
Research Services (NAM5, formerly
HNAM5)’’ is amended as follows:
Delete the ‘‘Division of Bioengineering
and Physical Science (NAM58, formerly
HNAM58)’’ in its entirety.
Delegations of Authority Statement:
All delegations and redelegations of
authority to officers and employees of
NIH that were in effect immediately
prior to the effective date of this
reorganization and are consistent with
this reorganization shall continue in
effect in them or their successors,
pending further redelegation.
Dated: September 28, 2007.
Raynard S. Kington,
Acting Director, National Institutes of Health.
[FR Doc. E7–19933 Filed 10–9–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Devices for Countercurrent
Chromatography
National Institutes of Health,
Public Health Service, HHS.
AGENCY:
E:\FR\FM\10OCN1.SGM
10OCN1
57596
Notice.
rwilkins on PROD1PC63 with NOTICES
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services, is
contemplating the grant of an exclusive
worldwide license to practice the
invention embodied in: HHS Ref. No. E–
321–2007 ‘‘Second Generation
Improved Spiral Tube Support for
Countercurrent Chromatography’’ to CC
Biotech LLC, a company incorporated
under the laws of the State of Maryland
having its headquarters in Rockville,
Maryland. The United States of America
The support compactly holds spirally
wound plastic tubing at a desired spiral
pitch without connection. When
mounted on the existing high-speed
countercurrent chromatographic
centrifuge, it will produce separation of
bioactive compounds including
proteins, nucleic acids, polysaccharides,
and small molecular weight compounds
from natural products without loss of
samples in the separation column.
The present invention is an
improvement on a spiral disc previously
reported under E–014–2003 (now
abandoned) which was published as
WO 2004/085020. That disc differed in
that the prior version the radial
channels represented in the figure on
the right (e.g., I1–O4; I4–O3, etc.) went all
the way through the disc and ended at
the outer wall and the center, thereby
creating a channel that forced tubing to
wrap around the device to re-enter the
spiral grooves. Here, the direction of the
tubing through the interleaved spiral
grooves is continuous and the transition
points between grooves are smoother.
The design effectively eliminates about
5 cm of ‘‘dead-space,’’ and allows for
VerDate Aug<31>2005
17:08 Oct 09, 2007
Jkt 214001
is the assignee of the rights of the above
inventions. The contemplated exclusive
license may be granted in a field of use
limited to devices and components for
centrifugal or countercurrent
chromatographic purification, isolation,
or preparation of biomolecules and
macromolecules.
DATES: Only written comments and/or
applications for a license received by
the NIH Office of Technology Transfer
on or before December 10, 2007 will be
considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Michael A. Shmilovich, Esq., Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 435–
5019; Facsimile: (301) 402–0220; E-mail:
shmilovm@mail.nih.gov. A signed
confidentiality nondisclosure agreement
will be required to receive copies of any
patent applications that have not been
published by the United States Patent
and Trademark Office or the World
Intellectual Property Organization.
SUPPLEMENTARY INFORMATION: The
patents and patent applications
intended for licensure disclose or cover
the following:
the plates to be stackable; which was
impossible with the previous design.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within sixty (60) days from the date of
this published notice, NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: October 1, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–19941 Filed 10–9–07; 8:45 am]
PO 00000
Frm 00084
Fmt 4703
Sfmt 4703
BILLING CODE 4140–01–P
DEPARTMENT OF THE INTERIOR
Fish and Wildlife Service
Proposed Candidate Conservation
Agreement With Assurances for Fisher
for the Stirling Management Area,
Sierra Pacific Industries, Butte,
Plumas, and Tehama Counties, CA
Fish and Wildlife Service,
Interior.
ACTION: Notice of availability; receipt of
application.
AGENCY:
SUMMARY: Sierra Pacific Industries
(Applicant) has applied to the U.S. Fish
and Wildlife Service (Service) for a 20year enhancement of survival permit for
the fisher (Martes pennanti) pursuant to
section 10(a)(1)(A) of the Endangered
E:\FR\FM\10OCN1.SGM
10OCN1
EN10OC07.006
ACTION:
Federal Register / Vol. 72, No. 195 / Wednesday, October 10, 2007 / Notices
Agencies
[Federal Register Volume 72, Number 195 (Wednesday, October 10, 2007)]
[Notices]
[Pages 57595-57596]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-19941]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Devices for
Countercurrent Chromatography
AGENCY: National Institutes of Health, Public Health Service, HHS.
[[Page 57596]]
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive worldwide license to practice the invention embodied in:
HHS Ref. No. E-321-2007 ``Second Generation Improved Spiral Tube
Support for Countercurrent Chromatography'' to CC Biotech LLC, a
company incorporated under the laws of the State of Maryland having its
headquarters in Rockville, Maryland. The United States of America is
the assignee of the rights of the above inventions. The contemplated
exclusive license may be granted in a field of use limited to devices
and components for centrifugal or countercurrent chromatographic
purification, isolation, or preparation of biomolecules and
macromolecules.
DATES: Only written comments and/or applications for a license received
by the NIH Office of Technology Transfer on or before December 10, 2007
will be considered.
ADDRESSES: Requests for a copy of the patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Michael A. Shmilovich, Esq., Office of
Technology Transfer, National Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-
5019; Facsimile: (301) 402-0220; E-mail: shmilovm@mail.nih.gov. A
signed confidentiality nondisclosure agreement will be required to
receive copies of any patent applications that have not been published
by the United States Patent and Trademark Office or the World
Intellectual Property Organization.
SUPPLEMENTARY INFORMATION: The patents and patent applications intended
for licensure disclose or cover the following:
[GRAPHIC] [TIFF OMITTED] TN10OC07.006
The support compactly holds spirally wound plastic tubing at a
desired spiral pitch without connection. When mounted on the existing
high-speed countercurrent chromatographic centrifuge, it will produce
separation of bioactive compounds including proteins, nucleic acids,
polysaccharides, and small molecular weight compounds from natural
products without loss of samples in the separation column.
The present invention is an improvement on a spiral disc previously
reported under E-014-2003 (now abandoned) which was published as WO
2004/085020. That disc differed in that the prior version the radial
channels represented in the figure on the right (e.g., I1-
O4; I4-O3, etc.) went all the way
through the disc and ended at the outer wall and the center, thereby
creating a channel that forced tubing to wrap around the device to re-
enter the spiral grooves. Here, the direction of the tubing through the
interleaved spiral grooves is continuous and the transition points
between grooves are smoother. The design effectively eliminates about 5
cm of ``dead-space,'' and allows for the plates to be stackable; which
was impossible with the previous design.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within sixty
(60) days from the date of this published notice, NIH receives written
evidence and argument that establishes that the grant of the license
would not be consistent with the requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: October 1, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E7-19941 Filed 10-9-07; 8:45 am]
BILLING CODE 4140-01-P